Cargando…

Preoperative Contrast-Enhanced Ultrasound (CEUS) Combined with (125)I Seeds Localization in Sentinel Lymph Node Biopsy for Breast Cancer

OBJECTIVE: To assess the clinical value of contrast-enhanced ultrasound (CEUS) technology in predicting axillary lymph nodes status before surgery, and to explore the feasibility of sentinel lymph nodes (SLNs) localization guided by CEUS combined with (125)I implantation for breast cancer. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Pengpeng, Zheng, Weizhen, Liu, Yanbing, Wang, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917323/
https://www.ncbi.nlm.nih.gov/pubmed/33658849
http://dx.doi.org/10.2147/CMAR.S296142
_version_ 1783657674898931712
author Zhou, Pengpeng
Zheng, Weizhen
Liu, Yanbing
Wang, Yongsheng
author_facet Zhou, Pengpeng
Zheng, Weizhen
Liu, Yanbing
Wang, Yongsheng
author_sort Zhou, Pengpeng
collection PubMed
description OBJECTIVE: To assess the clinical value of contrast-enhanced ultrasound (CEUS) technology in predicting axillary lymph nodes status before surgery, and to explore the feasibility of sentinel lymph nodes (SLNs) localization guided by CEUS combined with (125)I implantation for breast cancer. METHODS: From August 2017 to February 2019, 115 patients were included in this prospective study. Before surgery, a microbubble (SonoVue) was injected intradermally next to the areola. The enhancement patterns of SLNs were recorded and (125)I seeds were deployed into the enhanced nodes. Then, all patients underwent standard sentinel lymph node biopsy (SLNB) and all (125)I seeds were found out guided by a gamma detector in surgery. The localization was considered successful if (125)I seeds were implanted in/beside the nodes. RESULTS: SLNs in 103 cases were successfully identified, the success rate was 89.6% (103/115), 118 SLNs were detected in total. (125)I seeds were deployed successfully in 99 cases, and all of the (125)I-labeled SLNs were then successfully detected by combined method (radionuclides and blue dye). The accuracy of (125)I seeds localization was 96.1% (99/103). Based on the enhancement patterns recorded, 34 cases were predicted to have SLNs metastasis (metastasis in 27 cases and no metastasis in 7 cases confirmed by postoperative pathology) and 65 cases were predicted to have no SLNs metastasis (metastasis in 5 cases and no metastasis in 60 cases by pathology). The positive predictive value and negtive predictive value of CEUS in assessing axillary status were 79.4% (27/34) and 92.3% (60/65), respectively. The axillary metastasis rate in CEUS combined with (125)I seeds localization was 27.3% (27/99), while the metastasis rate in the combined method of SLNB was 32.3% (32/99). The sensitivity of (125)I seeds localization was 84.4% (27/32), the false-negative rate was 15.6% (5/32), and the consistency evaluation was excellent (Kappa value=0.880, P<0.001). CONCLUSION: CEUS combined with (125)I seeds implantation can locate SLNs accurately and has excellent consistency with the combined method. The enhancement patterns can provide helpful predicting information of axillary status preoperatively. However, more studies are needed to be carried out to verify our outcomes and explore the feasibility of applying CEUS technology in clinical work.
format Online
Article
Text
id pubmed-7917323
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79173232021-03-02 Preoperative Contrast-Enhanced Ultrasound (CEUS) Combined with (125)I Seeds Localization in Sentinel Lymph Node Biopsy for Breast Cancer Zhou, Pengpeng Zheng, Weizhen Liu, Yanbing Wang, Yongsheng Cancer Manag Res Original Research OBJECTIVE: To assess the clinical value of contrast-enhanced ultrasound (CEUS) technology in predicting axillary lymph nodes status before surgery, and to explore the feasibility of sentinel lymph nodes (SLNs) localization guided by CEUS combined with (125)I implantation for breast cancer. METHODS: From August 2017 to February 2019, 115 patients were included in this prospective study. Before surgery, a microbubble (SonoVue) was injected intradermally next to the areola. The enhancement patterns of SLNs were recorded and (125)I seeds were deployed into the enhanced nodes. Then, all patients underwent standard sentinel lymph node biopsy (SLNB) and all (125)I seeds were found out guided by a gamma detector in surgery. The localization was considered successful if (125)I seeds were implanted in/beside the nodes. RESULTS: SLNs in 103 cases were successfully identified, the success rate was 89.6% (103/115), 118 SLNs were detected in total. (125)I seeds were deployed successfully in 99 cases, and all of the (125)I-labeled SLNs were then successfully detected by combined method (radionuclides and blue dye). The accuracy of (125)I seeds localization was 96.1% (99/103). Based on the enhancement patterns recorded, 34 cases were predicted to have SLNs metastasis (metastasis in 27 cases and no metastasis in 7 cases confirmed by postoperative pathology) and 65 cases were predicted to have no SLNs metastasis (metastasis in 5 cases and no metastasis in 60 cases by pathology). The positive predictive value and negtive predictive value of CEUS in assessing axillary status were 79.4% (27/34) and 92.3% (60/65), respectively. The axillary metastasis rate in CEUS combined with (125)I seeds localization was 27.3% (27/99), while the metastasis rate in the combined method of SLNB was 32.3% (32/99). The sensitivity of (125)I seeds localization was 84.4% (27/32), the false-negative rate was 15.6% (5/32), and the consistency evaluation was excellent (Kappa value=0.880, P<0.001). CONCLUSION: CEUS combined with (125)I seeds implantation can locate SLNs accurately and has excellent consistency with the combined method. The enhancement patterns can provide helpful predicting information of axillary status preoperatively. However, more studies are needed to be carried out to verify our outcomes and explore the feasibility of applying CEUS technology in clinical work. Dove 2021-02-24 /pmc/articles/PMC7917323/ /pubmed/33658849 http://dx.doi.org/10.2147/CMAR.S296142 Text en © 2021 Zhou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Pengpeng
Zheng, Weizhen
Liu, Yanbing
Wang, Yongsheng
Preoperative Contrast-Enhanced Ultrasound (CEUS) Combined with (125)I Seeds Localization in Sentinel Lymph Node Biopsy for Breast Cancer
title Preoperative Contrast-Enhanced Ultrasound (CEUS) Combined with (125)I Seeds Localization in Sentinel Lymph Node Biopsy for Breast Cancer
title_full Preoperative Contrast-Enhanced Ultrasound (CEUS) Combined with (125)I Seeds Localization in Sentinel Lymph Node Biopsy for Breast Cancer
title_fullStr Preoperative Contrast-Enhanced Ultrasound (CEUS) Combined with (125)I Seeds Localization in Sentinel Lymph Node Biopsy for Breast Cancer
title_full_unstemmed Preoperative Contrast-Enhanced Ultrasound (CEUS) Combined with (125)I Seeds Localization in Sentinel Lymph Node Biopsy for Breast Cancer
title_short Preoperative Contrast-Enhanced Ultrasound (CEUS) Combined with (125)I Seeds Localization in Sentinel Lymph Node Biopsy for Breast Cancer
title_sort preoperative contrast-enhanced ultrasound (ceus) combined with (125)i seeds localization in sentinel lymph node biopsy for breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917323/
https://www.ncbi.nlm.nih.gov/pubmed/33658849
http://dx.doi.org/10.2147/CMAR.S296142
work_keys_str_mv AT zhoupengpeng preoperativecontrastenhancedultrasoundceuscombinedwith125iseedslocalizationinsentinellymphnodebiopsyforbreastcancer
AT zhengweizhen preoperativecontrastenhancedultrasoundceuscombinedwith125iseedslocalizationinsentinellymphnodebiopsyforbreastcancer
AT liuyanbing preoperativecontrastenhancedultrasoundceuscombinedwith125iseedslocalizationinsentinellymphnodebiopsyforbreastcancer
AT wangyongsheng preoperativecontrastenhancedultrasoundceuscombinedwith125iseedslocalizationinsentinellymphnodebiopsyforbreastcancer